3 Horrendous Health-Care Stocks This Week

Another month in 2014 has drawn to a close -- as has another week of horrendous performances by several health-care stocks. February is the shortest month of the year, but its final week proved to be quite a long one for some investors.

One of this week's big losers announced a secondary share offering that will lead to dilution of its stock. Another felt the brunt of allegations by a prominent short seller. And the third of our worst-performing companies did it the old-fashioned way -- by disappointing investors with its quarterly results.

Which companies made this week's list of horrendous health-care stocks? Find out by watching the following slideshow.

 

Our top stock of the year
Why settle for horrendous stocks? For that matter, why settle for just a "good" stock? After all, there's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

 


Read/Post Comments (7) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 01, 2014, at 10:58 AM, whopper wrote:

    WHERE did you author get that FDA has said that the allegations against Questcor (QCOR) made in the "report" sent to them "warrant an investigation" -----Were those exact words used, which have specific LEGAL and FDA process meaning? --To wit, was the word "INVESTIGATION" used? ---What WERE the exact words used by / in the source from which you learned this? ---And what is that source?

    My understanding thus far is that in response to an inquiry, the FDA made the standard, required--and highly limited--government response that acknowledges RECEIPT of the "report" and said only that they would/ were planning (as a result) to review the report.

  • Report this Comment On March 01, 2014, at 11:12 AM, awallejr wrote:

    You know if you are going to publish articles about stocks please do a better job at research. NOWHERE let me repeat NOWHERE did the FDA say Citron's lab findings warrant an investigation. That is a SERIOUS error on your part. There is a big difference between reviewing a report (reading it) and acting on it (investigating).

  • Report this Comment On March 01, 2014, at 11:17 AM, cameron12x wrote:

    Please cease and desist your erroneous reporting and your attempt to sensationalize this report.

  • Report this Comment On March 01, 2014, at 12:05 PM, Qcorinvestor wrote:

    There is a serious mistake in your report on QCOR. At no time has the FDA stated that the Citron report "warrants an investigation", nor has the FDA launched any sort of investigation on QCOR. This investigation talk are Citrons words only.

    Please correct your article. You are causing confusion and panic among the investing community.

  • Report this Comment On March 01, 2014, at 8:14 PM, MattBerry01 wrote:

    You mention AEGR's drop without mentioning the Department of Justice investigation? Investors were hoping for relief. They got none. AEGR investors were disappointed with what was NOT said by management.

    Investors were also hoping for closure with regards to the FDA Warning. They got none. We still don't know how well or poorly AEGR's response was received by the FDA.

    ~3footcrowbar

  • Report this Comment On March 02, 2014, at 4:01 PM, longjon1964 wrote:

    As several others have already pointed out, there is an error in your article about QCOR, regarding what the FDA has stated. The FDA has not stated that the Citron "report" warrants an investigation. They said they are reviewing the "report".

    This difference is a very important distinction. Please issue a correction.

  • Report this Comment On March 03, 2014, at 11:08 AM, aniustudent wrote:

    Ummm, I thought modern science had determined there were no more than 300 HoFH U.S. patients? Now AEGR has found who knows how many, but actually has almost 400 in the States on Juxtapid? Isn't this huge news? Specifically, if the one in a million stat is off for HoFH here, isn't it most likely to be off for the rest of the world, including Europe, Canada and Mexico where Juxtapid is now approved?

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2860316, ~/Articles/ArticleHandler.aspx, 12/20/2014 4:39:02 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement